Biopharma Dealmakers, Published online: 01 December 2025; doi:10.1038/d43747-025-00111-4 Bispecific and multispecific antibodies are gaining momentum in oncology research. They accounted for a quarter of the top 20 highest-grossing deals in the year to date, with many transactions focusing on Chinese assets.
Andrew Marshall. The year of the bispecific in oncology and beyond. // Biopharma Dealmakers. – 2025. – DOI: 10.1038/d43747-025-00111-4. – URL: https://www.nature.com/articles/d43747-025-00111-4
Andrew Marshall (2025). The year of the bispecific in oncology and beyond. Biopharma Dealmakers. https://doi.org/10.1038/d43747-025-00111-4
Andrew Marshall. “The year of the bispecific in oncology and beyond.” Biopharma Dealmakers, 2025. doi:10.1038/d43747-025-00111-4.
@article{Marshall2025,
title = {The year of the bispecific in oncology and beyond},
author = {Marshall, Andrew},
journal = {Biopharma Dealmakers},
year = {2025},
doi = {10.1038/d43747-025-00111-4},
url = {https://www.nature.com/articles/d43747-025-00111-4}
}
Eye, Published online: 19 November 2026; doi:10.1038/s41433-026-05030-x Comment on: ‘Association of accelerometer-monitored physical activity with incident cataract: epidemiological and genetic evidence’
Eye, Published online: 19 November 2026; doi:10.1038/s41433-026-05032-9 NAION during incretin-based therapy: an optic nerve head still adapted to hypertension
Eye, Published online: 19 November 2026; doi:10.1038/s41433-026-05016-9 Comparing refractive errors in CACNA1F and CABP4 -associated disease in a UK cohort
Eye, Published online: 19 November 2026; doi:10.1038/s41433-026-05018-7 Comment on: ‘Determinants of regression kinetics in observed stage 3 retinopathy of prematurity without plus disease’